ASK REDCHAT ANYTHING ABOUT MESOBLAST LIMITED
Mesoblast Limited (NASDAQ: MESO)
Listen to this Section
$15.46
+0.0200
(
+0.13% )
0.6K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| RexlemestrocelDetailsChronic lower back pain |
Phase 3 |
| Remestemcel-LDetailsInflammatory bowel disease, Bowel disorder, Crohns disease |
Failed |
| Remestemcel-L (mesenchymal stem cells)DetailsCOVID-19 |
Failed |
Market Data
|
| Open |
$15.46 |
| Previous Close |
$15.44 |
| Volume |
0.6K |
| Market Cap |
$2.00B |
| Day Range |
$15.46 - $15.46 |
| 52 Week Range |
$10.96 - $21.50 |
| Shares Outstanding |
129.28M |
| Change % |
+0.13% |
| Net Change |
▲ 0.0200 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 2009 |
| Country | Australia |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |